# BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence

> **Open Intelligence Dossier** · First detected: 2026-10-13 18:00 UTC · Category: Business

## Executive Summary
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence" is generating significant coverage in the Business category, with 7 articles from 7 distinct sources tracked by PULSE so far.


Outlets currently covering the story include Oncodaily, Yahoo Finance, TradingView and GenomeWeb. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| BioSpace | BioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survival | [Source Link](https://news.google.com/rss/articles/CBMiywFBVV95cUxQTXJCdGRSbndpZ1ByT0dJcU9ZT1lpWE52am5zMV9hQ0ctcE42WVpkTXZ3TEVNSEhjZGRlWEhZV1RfVURfalZIRS05XzN0bG1SVmY1dEJCSnlDWXpnNWJRYXpxV01PY2h3NldWMUxtYXQ2T3ZMalRXQ29uV0NMOWg2WmVkQV95bVFzMGY0TWx6ekxKXzdLWkV1Z2NOSVppUWI0Y094LTVNNlAwcDNvYTV3SzJza3ZaTTQzYTRobjhQdHJGdjBKc1JrQXMzcw?oc=5) |
| The Globe and Mail | Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success? | [Source Link](https://news.google.com/rss/articles/CBMiowJBVV95cUxPcF92OEJrdnpUTTJQWEgzb3pNR1Q5c1l5Z3VLY1FKTExYWDJEUjFFQVlIc1gxTklCUnk4bjd2ekRsOXhhMWJqbkkwdGdhUDduZHZUVDVlOVFJRnJUNThrQWRVV0tNZFJGeUhpb19yZmpfRFdrbjU3SmJqVGNGVUdkb1dCQlZUb1ZFMkFjeWhkR0d6WGprNTZRVmV5QkhrQ0c2LWMtTjdEZGZZakZmMXA2N1BpdXVOMktHZFBnbE95allTeGZZcnRZQmphSzdsTEp0RXJqbFVuc2VzVmFUeWpqV01IRkwydVlCcEZNV1lTeS1WMmtGMGZ0OTNJbnRXdzhZOTVsR004cnN3Tm9wUTBLb0VIbmZna3QwbXQtWTZFYmU3N0U?oc=5) |
| TradingKey | Biontech SE Stock (BNTX) Closed Down by 7.13% on Oct 13: Drivers Behind the Movement | [Source Link](https://news.google.com/rss/articles/CBMiiwFBVV95cUxOdW9FV3FVa0ZSVlVMdkstMGc4c3NNUU1SMjlMQWJfS2NyZHJqc1o2NGlJRGtsZHdXUnI0N20yZ2JOLXM4WklVaXpqRzdEZEJ4dXg1ZmNjVUxBNWxna3lXNVZVeGJxMkRHYXNiRGhQOUhXRzBpU0htODZRODJJcmQxdmdzUVdoYmlVR2M4?oc=5) |
| Reuters | BioNTech's mRNA cancer therapy misses first goal in head and neck trial | [Source Link](https://news.google.com/rss/articles/CBMitwFBVV95cUxOZTR3dEhQVG9QN3dNSlpFQy1sS3l2N1VVODhBOGFUV2ltQS13LXJ4T1lWM2pIeW5na2FlT0d6SE5FU29KSDM4ZGpETnNuNFh3QkVGRDduT18wNVBQc0VSZkhwWmEyZW15YlVIdXhGTTktUnc0elRVbE11OWVuNG9zZktIaGRtQW00N1lPdGVxTEtib2VIc1NWLVIxZ0o5cjBET29jNHpqeGFrREJpVUx4c0M4RWlucGs?oc=5) |
| OncLive | Tenumomeran/Raplemomeran Plus Pembrolizumab Misses PFS End Point in HPV16+ HNSCC | [Source Link](https://news.google.com/rss/articles/CBMirAFBVV95cUxOQjduTEhJTVVodDJNZzREN3JJNkkzaTFHc2gybWhJalBoVTFjRVRhNGNlUHBqeVBaNUdzYUJNZ3JhWlp6TS1GTXNLUVBRS1I3eGVoYUZOeUlhZXA2cmlwSFBoMzlwX0lZTnllM2dBTV9INjQ1QUtSVk9VX2FOLUtLc284S2FwYkRXM3JxN2JKQ2JNNDRTMHkxdm10TkQtX2pTblQyV0lxeVBVV2t5?oc=5) |
| FirstWord Pharma | BioNTech's HPV-targeted cancer vaccine misses PFS goal | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTFA4dUFyeS1rd25UYmNxbklPenpFcDJ3ZWRqZF9rWWF0VHVUWUQ2QUpuVlhnN21JdlZsaHBNUWxib1pLSDdSemUtQWVGcmN2VmxfcmhZ?oc=5) |
| TradingView | BioNTech’s Cancer Drug Misses A Key Trial Goal – Citi Says Survival Data Could Preserve ‘A Meaningful Development Path’ | [Source Link](https://news.google.com/rss/articles/CBMihwJBVV95cUxPMXZZbXNFeTFMaVZ0ckZwTzlRZzBpUGNIX0Y2SktZV3AtSUg2MFRkSmxENEVJcGZUSEQtWmYtVUpNTXZtVnFRbkVMbVN1TDRfMkpNZ1ZZWE5LQ1U5NnpJR0RnWkFSaWgyY2t0SmxPSHoyNFBPWDJZLTJWNVRuVGkzUllFYXg5UWlQMWlhYmFibzgyY2w0LWV6djdqMmdmU3JPbWVIemgyaXdrWVdWb2dPc3ZDNDFJa1NYZnhHbmJadlV0a09UbHFTVU9EWXk4V2pQY21BRGNsVUZiMjVGenMzeUJLRlpaSk5uVE9DTVJrT2M5Q0VkT0VmTi1Udy1obDNCSnpsbjBMaw?oc=5) |
| Oncodaily | BioNTech Shares Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy in Metastatic HPV16-Positive HNC | [Source Link](https://news.google.com/rss/articles/CBMic0FVX3lxTE85V3B6cHdvWUYzZEdGclBSVElKSjRfa1BETkd5enQ1RmFqbmxNU0JDWVROTFBqU29ScUFHQWN3SENhWkZwS0pGcGlGTEZxUDV0eEg2alNyelpGNTk4bnBBTXp6S21aM2pydGpjclp2MWhwVXc?oc=5) |
| Yahoo Finance | BioNTech stock falls after cancer trial misses key endpoint | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxQbmJqVjJNTW1VdzZHWHpyaUdLZHVsRW52QTBrQ01WT1hFYldDTUgzNm5lLUlyMXRzdDVVak1XTWhIZ1kxVThiQXVuUHVucWhwcVRKVzBqemFfR2hESnc5M05UZEVKNlZQcjRRNGVNeXByZy1Cdmh0ZkYyeWx4X1ZZWkRUU0tKTjRRMFVtRmtoS21zQmRvQUpUdjB3?oc=5) |
| TradingView | BioNTech's mRNA cancer therapy misses first goal in head and neck trial | [Source Link](https://news.google.com/rss/articles/CBMi2AFBVV95cUxOQkpUaXRhY2JBNDR3Mk05VmN4SmtNSUlBMkF5TG16d3llUERPMlRGeGpaLWRoXzdHWkRoUFlHdTVFOGV0S055MHV4dmg4d0J6UDFKVmprM2dtSVBaQmE1ZDdIN2d0ODk2X1Qtem9WTzM1YkxoQWhOeFFoNkFMaHZTUW1teGVaUGgwVk9LQmJiNkNsczRFRDVGUnk5UWs1MGpwaDNtQ0xuX3NuSmdlempzaUZFeUdYenlhOGhOQUFCb2c3TEt5N3R3a3JqYjNQVlVyTnFuZGc0NWE?oc=5) |
| GenomeWeb | BioNTech mRNA Trial Will Keep Tracking Overall Survival After Initial Progress-Free Survival Failure | [Source Link](https://news.google.com/rss/articles/CBMirAFBVV95cUxPenRGdjBSS1VnZ202SzNVLXRYcnpGbi1LRmxPV0VJZ3JwZmJFSjBEOC1zMVU4V1h4VjJVUERFWlJzMWRCaGpOb3Y2YmtPQ2pYR2RDa3ROY254c254UHViQy0zNWZIdld6YUxlZHZRVnJycVJHNkNDNVZiQzJUNWNlbGd3MGVvQTRqLTUyZW85cVhyT0xKT2hnZzBaUW0wUzZxUFNLZ3lDc29FZldR?oc=5) |
| CancerNetwork | BNT113/Pembrolizumab Misses PFS End Point in HPV16+ Head and Neck Cancer | [Source Link](https://news.google.com/rss/articles/CBMiqgFBVV95cUxQc1VuMmtnSDZtNjJVV2R0NS1hdU5QSVdMcUgweW5qRnlIQ3kwazN6NWluX0dYbmc1M1p4SFk2UzFNRUJsMDA0N2w1cHgtVDljSkVKUzRncmxScnpnNzlldFpVTnBuSUliYTBESmZiakZfUVhPamgtVWY3WmJkZU1VbldlRFpJWmRTYUVqUWxxbEZhTTlqMjgxZE9ocjBUNGhUSGlvTTk4VTVGQQ?oc=5) |
| Bloomberg.com | BioNTech Says Cancer Treatment Didn’t Help in Early Analysis | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxOSHI1X2ZCM0E4cUVTVWlIUUZNVWQ3VElHVGpKRkprUG03MlRTb0t6a3pnd2xxWEhlbFk0bWpLUVNiaGZnR294Q2ZQVERnTkxFSmFMWVNUbzRwZDhKWm9UQnk0dlYxdzhveDUtYmlVVm1DZ2FkMFBjbzIyUGNpQktGcF9Pb1lBQkNIbXY5R08tT2lEeUswUXhkR0g4WnNHd3lUeUhTZi0tRUFPUXlrNmtuUw?oc=5) |
| Fierce Biotech | BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence | [Source Link](https://news.google.com/rss/articles/CBMixwFBVV95cUxOaVZuRk1zMFhhQmhFQmZVak0zXzV5NjFfTGtWVGFaYnVJVk1EbG42eGFpaHp1eVNRam4zaHE0aDZ6eHhtcU5MRlBqVXRPc2dWdHdYS3pMOUlaUlBvRXhOcmZrNDExRllBWjZ3Nm1pRTRud3NETzFHOWlmWWc3NTM4YmhoMGcwTkJBYXB2MHNmR0poWWEyRklkWXdONDdZbXhTYXEzalJfRER1TmJ5d1I3M3BUdy02aTMxVWlPbS1PTW9haVpTWGFZ?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-10-13/biontech-s-mrna-cancer-vaccine-fails-phase-3-test-significantly-denting*